Sanofi Ventures

Sanofi Ventures is a corporate venture capital (CVC) unit wholly owned by Sanofi S.A. It invests with a dual mandate: to generate financial returns and to provide a strategic window into emerging science for the parent pharmaceutical company. This means it can invest in companies at stages too early for Sanofi's business development teams to partner with or acquire, acting as an external innovation scouting and de-risking mechanism that a purely financial VC would not be.

Yes. Sanofi Ventures states that it leads financings and takes board seats alongside its portfolio company founders. This active direct-investment posture distinguishes it from passive fund-of-funds models, allowing it to work closely with management teams to drive long-term value creation from Seed stage through Series B and beyond.

Sanofi Ventures operates at arm's length from the parent company's internal R&D engine. It invests equity into external startups, which then develop their technologies independently. The CVC unit creates an optionality pipeline; if a portfolio company reaches a de-risked stage, Sanofi S.A. may later choose to partner with or acquire it, but the investment itself does not grant the parent any operational control over the startup's science during development.

The firm's mandate centers on biotherapeutics and digital health. This includes companies developing new drug platforms, novel therapeutic modalities, and health technologies that focus on improving patient outcomes and transforming the practice of medicine.

Sanofi Ventures maintains a transatlantic investment posture. It has offices in Palo Alto, Cambridge, and New York to cover the US East and West coast innovation ecosystems, alongside a presence in Paris to access European life sciences startups.